- CBD or THC? Cannabis Product Labels Often Mislead, Study Finds
- AHA News: Straight Answers to Common Questions About COVID-19 Vaccines
- U.S. Health Agencies Call for Pause in J&J COVID Vaccine After 6 People Develop Clots
- Therapeutic Cancer Vaccine Shows Promise Against Multiple Tumor Types
- Health Highlights: April 13, 2021
- Newborns Won’t Get COVID Through Infected Mom’s Breast Milk: Study
- Physically Active at Work? It’s Not as Healthy as Leisure Exercise
- Americans Are Eating Less Healthily Everywhere, Except at School
- U.K. Variant Won’t Trigger More Severe COVID, Studies Find
- FDA Approves First AI Tool to Boost Colonoscopy Accuracy
Generic Effexor XR Approved
TUESDAY, June 29The first generic version of Effexor extended release capsules (venlafaxine hydrochloride) to treat major depressive disorder has been approved by the U.S. Food and Drug Administration.
Prescribing information for the generic version of Effexor XR may differ from that of the brand name drug because of various patents held by the brand name drug’s maker, Wyeth Pharmaceuticals, the FDA said in a news release. But the same safety warnings will apply.
The generic version will be manufactured by Teva Pharmaceuticals, based in Wales, Penn.
The drug’s label includes a warning that antidepressants may raise the risk of suicidal thoughts or tendencies among some children, teens and young adults, the agency said.
More information
To learn more about this drug, visit the U.S. National Library of Medicine.
Source: HealthDay
